The Medicines and Healthcare Regulatory Authority (MHRA) has released the outcome of a review into the classification of glucosamine containing products (GCPs) and signalled its intention to reclassify GCPs with a base glucosamine level greater than 1178mg/day as medicinal products. These products will now require a marketing authorisation prior to any advertising or supply over the counter. GCPs containing less than 1178mg/day will continue to be sold as food supplements.
All GCPs are currently classified as food products and used to alleviate joint problems. They were routinely prescribed on the NHS, but a drive for evidence-based treatments on the NHS meant that they fell out of favour, as it was thought the money could be better spent elsewhere.
For more information, click here.